Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10304887 | 0.84 | L3MBTL1 (0.44) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4440118 | 0.84 | L3MBTL1 (0.46) | POLBSMN1; SMN2ALDH1A1HPGDCTSK | |
| SCHEMBL17901791 | 0.83 | CYP3A4 (0.50) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4400005 | 0.83 | CYP3A4 (0.43) | LMNASMN1; SMN2CYP3A4CYP2C19HTT | |
| SCHEMBL19792871 | 0.79 | CYP3A4 (0.56) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4394457 | 0.79 | CYP3A4 (0.45) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL8392919 | 0.78 | HTT (0.47) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL21538501 | 0.78 | HTT (0.47) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL22264520 | 0.78 | ALDH1A1 (0.54) | POLBLMNASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4400001 | 0.76 | CYP3A4 (0.43) | SMN1; SMN2CYP3A4CYP2C19HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | POLB 1716/4885LMNA 1556/4885SMN1; SMN2 4034/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | POLB 1384/4885LMNA 3150/4885SMN1; SMN2 3061/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | POLB 1077/4885LMNA 2089/4885SMN1; SMN2 1848/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | POLB 1262/4885LMNA 1928/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.